Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Accumulated Expenses: 2021-2024

Historic Accumulated Expenses for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $23.9 million.

  • Amylyx Pharmaceuticals' Accumulated Expenses fell 61.41% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year decrease of 61.41%. This contributed to the annual value of $23.9 million for FY2024, which is 58.51% down from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Accumulated Expenses is $23.9 million, which was down 58.51% from $57.7 million recorded in FY2023.
  • Over the past 5 years, Amylyx Pharmaceuticals' Accumulated Expenses peaked at $57.7 million during FY2023, and registered a low of $13.0 million during FY2021.
  • For the 3-year period, Amylyx Pharmaceuticals' Accumulated Expenses averaged around $40.0 million, with its median value being $38.3 million (2022).
  • In the last 5 years, Amylyx Pharmaceuticals' Accumulated Expenses spiked by 194.16% in 2022 and then plummeted by 58.51% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Accumulated Expenses (Yearly) stood at $13.0 million in 2021, then skyrocketed by 194.16% to $38.3 million in 2022, then skyrocketed by 50.67% to $57.7 million in 2023, then plummeted by 58.51% to $23.9 million in 2024.